Advertisement

Hormones

pp 1–7 | Cite as

Selective antagonism of CRF1 receptor by a substituted pyrimidine

  • Stelios Sakellaris
  • Minos-Timotheos Matsoukas
  • Vlasios Karageorgos
  • Smaragda Poulaki
  • Bhimanna Kuppast
  • Andrew Margioris
  • Maria Venihaki
  • Hesham Fahmy
  • George LiapakisEmail author
Original Article
  • 2 Downloads

Abstract

The corticotrophin-releasing factor (CRF) and its type 1 receptor (CRF1R) regulate the hypothalamic-pituitary-adrenal axis, as well as other systems, thus playing a crucial role in the maintenance of homeostasis. Non-peptide CRF1R-selective antagonists exert therapeutic effects on experimental animals with abnormal regulation of their homeostatic mechanisms. However, none of them is as yet in clinical use. In an effort to develop novel small non-peptide CRF1R-selective antagonists, we have synthesized a series of substituted pyrimidines described in a previous study. These small molecules bind to CRF1R, with analog 3 having the highest affinity. Characteristic structural features of analog 3 are a N,N-bis(methoxyethyl)amino group at position 6 and a methyl in the alkythiol group at position 5. Based on the binding profile of analog 3, we selected it in the present study for further pharmacological characterization. The results of this study suggest that analog 3 is a potent CRF1R-selective antagonist, blocking the ability of sauvagine, a CRF-related peptide, to stimulate cAMP accumulation in HEK 293 cells via activation of CRF1R, but not via CRF2R. Moreover, analog 3 blocked sauvagine to stimulate the proliferation of macrophages, further supporting its antagonistic properties. We have also constructed molecular models of CRF1R to examine the interactions of this receptor with analog 3 and antalarmin, a prototype CRF1R-selective non-peptide antagonist, which lacks the characteristic structural features of analog 3. Our data facilitate the design of novel non-peptide CRF1R antagonists for clinical use.

Keywords

Corticotropin-releasing factor Receptor Antagonists Structure Signaling 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Grants or fellowship supports

This work was supported by ELKE grant K.A. 4373 (George Liapakis) and ELKE grant K.A. 3330 (Andrew Margioris).

References

  1. 1.
    Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213(4514):1394–1397Google Scholar
  2. 2.
    Owens MJ, Nemeroff CB (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43(4):425–473Google Scholar
  3. 3.
    Ramot A, Jiang Z, Tian JB et al (2017) Hypothalamic CRFR1 is essential for HPA axis regulation following chronic stress. Nat Neurosci 20(3):385–388Google Scholar
  4. 4.
    Chrousos GP (2009) Stress and disorders of the stress system. Nat Rev Endocrinol 5(7):374–381Google Scholar
  5. 5.
    Chrousos GP (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332(20):1351–1362Google Scholar
  6. 6.
    Martinez V, Tache Y (2006) CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 12(31):4071–4088Google Scholar
  7. 7.
    Venihaki M, Majzoub J (2002) Lessons from CRH knockout mice. Neuropeptides 36(2–3):96–102Google Scholar
  8. 8.
    Slominski AT, Zmijewski MA, Zbytek B et al (2013) Key role of CRF in the skin stress response system. Endocr Rev 34(6):827–884Google Scholar
  9. 9.
    Dermitzaki E, Liapakis G, Androulidaki A et al (2014) Corticotrophin-releasing factor (CRF) and the urocortins are potent regulators of the inflammatory phenotype of human and mouse white adipocytes and the differentiation of mouse 3T3L1 pre-adipocytes. PLoS One 9(5):e97060Google Scholar
  10. 10.
    Karalis K, Sano H, Redwine J et al (1991) Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254(5030):421–423Google Scholar
  11. 11.
    Henckens MJ, Deussing JM, Chen A (2016) Region-specific roles of the corticotropin-releasing factor-urocortin system in stress. Nat Rev Neurosci 17(10):636–651Google Scholar
  12. 12.
    Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160(1):1–12Google Scholar
  13. 13.
    Reul JM, Holsboer F (2002) Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2(1):23–33Google Scholar
  14. 14.
    Nielsen DM (2006) Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants? Life Sci 78(9):909–919Google Scholar
  15. 15.
    Rivier JE, Rivier CL (2014) Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance. Front Neuroendocrinol 35(2):161–170Google Scholar
  16. 16.
    Grammatopoulos DK, Chrousos GP (2002) Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 13(10):436–444Google Scholar
  17. 17.
    Shaham Y, de Wit H (2016) Lost in translation: CRF1 receptor antagonists and addiction treatment. Neuropsychopharmacology 41(12):2795–2797Google Scholar
  18. 18.
    Spierling SR, Zorrilla EP (2017) Don't stress about CRF: assessing the translational failures of CRF1antagonists. Psychopharmacology 234(9–10):1467–1481Google Scholar
  19. 19.
    Muller MB, Zimmermann S, Sillaber I et al (2003) Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6(10):1100–1107Google Scholar
  20. 20.
    Timpl P, Spanagel R, Sillaber I et al (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19(2):162–166Google Scholar
  21. 21.
    Zorrilla EP, Koob GF (2010) Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 15(9–10):371–383Google Scholar
  22. 22.
    Fahmy H, Spyridaki K, Kuppast B, Liapakis G (2012) The "homeostasis hormone" and its CRF(1) receptor. From structure to function. Hormones (Athens) 11(3):254–271Google Scholar
  23. 23.
    Stengel A, Goebel M, Million M et al (2009) Corticotropin-releasing factor-overexpressing mice exhibit reduced neuronal activation in the arcuate nucleus and food intake in response to fasting. Endocrinology 150(1):153–160Google Scholar
  24. 24.
    Liapakis G, Venihaki M, Margioris A, Grigoriadis D, Gkountelias K (2011) Members of CRF family and their receptors: from past to future. Curr Med Chem 18(17):2583–2600Google Scholar
  25. 25.
    Hillhouse EW, Grammatopoulos DK (2006) The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27(3):260–286Google Scholar
  26. 26.
    Gkountelias K, Papadokostaki M, Javitch JA, Liapakis G (2010) Exploring the binding site crevice of a family B G protein-coupled receptor, the type 1 corticotropin releasing factor receptor. Mol Pharmacol 78(4):785–793Google Scholar
  27. 27.
    Grace CR, Perrin MH, DiGruccio MR et al (2004) NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proc Natl Acad Sci U S A 101(35):12836–12841Google Scholar
  28. 28.
    Pioszak AA, Parker NR, Suino-Powell K, Xu HE (2008) Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1. J Biol Chem 283(47):32900–32912Google Scholar
  29. 29.
    Hoare SR, Sullivan SK, Ling N, Crowe PD, Grigoriadis DE (2003) Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol Pharmacol 63(3):751–765Google Scholar
  30. 30.
    Kuppast B, Spyridaki K, Liapakis G, Fahmy H (2014) Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands. Eur J Med Chem 78:1–9Google Scholar
  31. 31.
    Venihaki M, Gravanis A, Margioris AN (1996) Kappa opioids exert a strong antiproliferative effect on PC12 rat pheochromocytoma cells. Peptides 17(3):413–419Google Scholar
  32. 32.
    Hollenstein K, Kean J, Bortolato A et al (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499(7459):438–443Google Scholar
  33. 33.
    Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461Google Scholar
  34. 34.
    Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM (2013) Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc Natl Acad Sci U S A 110(13):5211–5216Google Scholar
  35. 35.
    Spyridaki K, Matsoukas MT, Cordomi A et al (2014) Structural-functional analysis of the third transmembrane domain of the Corticotropin-releasing factor type 1 receptor: Role in activation and allosteric antagonism. J Biol Chem 289(27):18966–18977Google Scholar
  36. 36.
    Cordomi A, Liapakis G, Matsoukas MT (2017) Understanding Corticotropin releasing factor receptor (CRFR) activation using structural models. Curr Mol Pharmacol 10(4):325–333Google Scholar
  37. 37.
    McGillis JP, Park A, Rubin-Fletter P et al (1989) Stimulation of rat B-lymphocyte proliferation by corticotropin- releasing factor. J.Neurosci.Res. 23(3):346–352Google Scholar
  38. 38.
    Singh VK (1989) Stimulatory effect of corticotropin-releasing neurohormone on human lymphocyte proliferation and interleukin-2 receptor expression. J Neuroimmunol 23:257–262Google Scholar
  39. 39.
    Jessop DS, Harbuz MS, Snelson CL, Dayan CM, Lightman SL (1997) An antisense oligodeoxynucleotide complementary to corticotropin- releasing hormone mRNA inhibits rat splenocyte proliferation in vitro. J.Neuroimmunol. 75(1–2):135–140Google Scholar

Copyright information

© Hellenic Endocrine Society 2019

Authors and Affiliations

  • Stelios Sakellaris
    • 1
  • Minos-Timotheos Matsoukas
    • 2
  • Vlasios Karageorgos
    • 1
  • Smaragda Poulaki
    • 3
  • Bhimanna Kuppast
    • 4
  • Andrew Margioris
    • 3
  • Maria Venihaki
    • 3
  • Hesham Fahmy
    • 4
  • George Liapakis
    • 1
    Email author
  1. 1.Department of Pharmacology, School of MedicineUniversity of CreteCreteGreece
  2. 2.Department of PharmacyUniversity of PatrasPatrasGreece
  3. 3.Department of Clinical Chemistry, School of MedicineUniversity of CreteCreteGreece
  4. 4.Department of Pharmaceutical Sciences, College of PharmacySouth Dakota State UniversityBrookingsUSA

Personalised recommendations